

June 06, 2015

✓ The Dy. General Manager (Listing Dept.)  
Bombay Stock Exchange Limited  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
(BSE Scrip Code: 500420)

~~The Manager - Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai - 400 051  
(NSE Scrip Code: TORNTPHARM)~~

Dear Sir,

**Sub.: Code of Fair Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015**

Pursuant to Regulation 8 of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ('Regulations'), the Board of Directors has formulated "Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information" ('Code of Fair Disclosure') of the Company. Further, the Board had authorised Committee of Directors to appoint Chief Investor Relations Officer for the purpose of this Code and accordingly the Committee of Directors has appointed Chief Financial Officer as the Chief Investor Relations Officer. The Code is enclosed herewith for your record.

The above is for your information and record.

Thanking you.

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

  
MAESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY

Encl.: A/a

**Code of Practices and Procedures for Fair Disclosure of  
Unpublished Price Sensitive Information**

**Introduction :**

The SEBI has notified the Securities and Exchange Board of India (SEBI) (Prohibition of Insider Trading) Regulations, 2015 ("the Regulations") on 15<sup>th</sup> January, 2015 which has repealed the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Pursuant to Regulation 8, sub regulation (1), every listed Company is required to adopt the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information in order to protect investor's interest.

In compliance with the above Regulation, the Board of Directors of Torrent Pharmaceuticals Limited, (the Company) in their meeting held on 15<sup>th</sup> May, 2015 has approved the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information. This Code replaces the "Code of Corporate Disclosure Practices for Prevention of Insider Trading" followed by the Company.

**Principles to be adhered to as practices and procedures for fair disclosure of Unpublished Price Sensitive Information:**

1. The Company shall promptly make disclosure of unpublished price sensitive information that would impact price discovery (**material events**) no sooner than credible and concrete information comes into being in order to make such information generally available.
2. The Company shall make uniform and universal dissemination of Material Events to avoid selective disclosure.
3. The Company shall appoint a senior officer designated as chief investor relations officer who shall deal with the dissemination of information and disclosure of material events.
4. The Company shall make prompt dissemination of unpublished price sensitive information that gets disclosed selectively, inadvertently or otherwise to make such information generally available.
5. The Company shall make appropriate and fair response to queries on news reports and requests for verification of market rumours by regulatory authorities.

In this regard, the general policy of the Company shall be not to respond to market rumor or speculations unless required by the regulatory authorities. The standard response shall be "it is the Company's policy not to comment rumours or speculations". However, any rumours



that have or is likely to have a substantial effect on the price of the Company's securities shall be dealt with by the CISO after necessary due-diligence, in accordance with the Regulations.

6. The Company shall ensure that information shared with analysts and research personnel is not unpublished price sensitive information.
7. The Company shall develop and implement best practices to make transcripts or records of proceedings of meetings with analysts and other investor relations conferences on the official website simultaneously with such meet to ensure official confirmation and documentation of disclosures made.

At least two Company representatives should preferably be present at meetings with analysts, media persons and institutional investors.

Unanticipated questions may be taken on notice and a considered response given later. If the answer includes Unpublished Price Sensitive Information, a public announcement should be made before such response.

8. The Company shall handle all Unpublished Price Sensitive Information on a need-to-know basis.

Explanation 1: "need to know basis" means that Unpublished Price Sensitive Information should be disclosed only to those within the Company who need the information to discharge their duty and whose possession of such information will not give rise to a conflict of interest or appearance of misuse of the information.

Explanation 2: "Unpublished Price Sensitive Information" means any information, relating to Company or its securities, directly or indirectly, that is not generally available which upon becoming generally available, is likely to materially affect the price of the securities and shall, ordinarily including but not restricted to, information relating to the following:

- a. financial results;
- b. dividends;
- c. change in capital structure;
- d. mergers, de-mergers, acquisitions, delistings, disposals and expansion of business and such other transactions;
- e. changes in key managerial personnel; and
- f. material events in accordance with the listing agreement

Words and expressions used and not defined in the Code shall have the same meanings respectively assigned to them in the "Code of Conduct to Regulate, Monitor and Report Trading by Insiders"

